BiotechTube
Cellarcus Biosciences

Cellarcus Biosciences

Cambridge, United States· Est.
cellarcus.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2019, Cellarcus Biosciences is a private, pre-revenue platform company focused on the critical need for standardization in the rapidly growing extracellular vesicle research and diagnostics field. Its proprietary vFC™ platform provides a validated, no-wash assay workflow that allows researchers to accurately count, size, and analyze protein cargo on single EVs using existing laboratory flow cytometers. By offering both products and CRO services, Cellarcus is positioning itself as an essential tools provider to academic, biopharma, and diagnostic labs seeking to develop EV-based biomarkers and therapies.

Cell TherapyCRISPRSynthetic Biology

Technology Platform

Vesicle Flow Cytometry (vFC™) platform comprising assay kits (vFC™), calibration standards (vCal™), and optimized antibodies (vTag™) for standardized, no-wash, single extracellular vesicle analysis on standard flow cytometers.

Opportunities

The rapidly expanding field of extracellular vesicle research and therapeutic development creates a large and growing need for standardized, reliable analysis tools.
Cellarcus's ability to provide both products and CRO services positions it to capture revenue from both academic/biopharma research and from partners advancing EV-based diagnostics and therapeutics.

Risk Factors

Key risks include competition from alternative EV analysis technologies, the challenge of driving adoption of a new standard in a fragmented research community, and dependence on the overall growth rate and funding environment for EV science.
Execution risks in scaling manufacturing and sales are also present.

Competitive Landscape

Cellarcus competes with providers of nanoparticle tracking analysis (NTA) instruments, traditional flow cytometry reagent companies adapting to EVs, and other specialized EV isolation/analysis startups. Its primary competitive advantage is the integrated, standardized, and no-wash workflow of its vFC™ platform designed specifically for direct biofluid analysis, addressing a major pain point in the field.

More companies in Diagnostics & Precision Medicine →More companies in United States →